BANNOCKBURN, Illinois, September 19, 2011 /PRNewswire/ --
Effective October 1, 2011, Pinnacle Biologics Inc., grants exclusive distribution rights for PHOTOFRIN® and PHOTOBARR® to ALKOPHARMA SA for most of European countries, Middle East and most South East Asian Countries.
"We are pleased to expand our strategic partnership with members of the ALKOGROUP companies, ALKOPHARMA and GENOPHARM, through the addition of a second product and expanded territories to our already successful collaboration in Western Europe. ALKOPHARMA and GENOPHARM possess medical and regulatory expertise, scientific background, sizeable commercial infrastructure and resources to partner with Pinnacle in expanding PDT technology in the new territories, as well as solidify the presence of PDT in Europe where the product is already available," said Guillermo Herrera, Executive Chairman of Pinnacle Biologics.
"PDT with PHOTOFRIN® and PHOTOBARR® represents an exceptional opportunity for us to offer a unique and innovative technology for the treatment of certain forms of Cancers. We are excited about this opportunity and are well positioned to support and deliver benefits of Photodynamic Therapy to Healthcare Providers and patients," said Alain Bouaziz founder of ALKOGROUP.
For further information concerning products and technology, please visit our website: http://www.photofrin.com and http://www.pinnaclebiologics.com. For more information regarding ALKOPHARMA and GENOPHARM visit http://www.genopharm.eu
Contact Information: Julie Jenkins, +1-847-283-7933 or email email@example.com
SOURCE Pinnacle Biologics